OncoMatch/Clinical Trials/NCT06369155
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Is NCT06369155 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Azenosertib for uterine serous carcinoma.
Treatment: Azenosertib — This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Allowed: MSH2 deficient
participants must have a known tumor MSI or MMR status and those participants with MSI-high or MMR-deficient tumors must have already received prior therapy with a PD1 or PD-L1 immune checkpoint inhibitor or be deemed not to be a candidate for immune checkpoint therapy
Allowed: MSH6 deficient
participants must have a known tumor MSI or MMR status and those participants with MSI-high or MMR-deficient tumors must have already received prior therapy with a PD1 or PD-L1 immune checkpoint inhibitor or be deemed not to be a candidate for immune checkpoint therapy
Allowed: MLH1 deficient
participants must have a known tumor MSI or MMR status and those participants with MSI-high or MMR-deficient tumors must have already received prior therapy with a PD1 or PD-L1 immune checkpoint inhibitor or be deemed not to be a candidate for immune checkpoint therapy
Allowed: PMS2 deficient
participants must have a known tumor MSI or MMR status and those participants with MSI-high or MMR-deficient tumors must have already received prior therapy with a PD1 or PD-L1 immune checkpoint inhibitor or be deemed not to be a candidate for immune checkpoint therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — advanced/metastatic or adjuvant (if recurrence within 12 months)
Participants must have had one prior platinum-based chemotherapy regimen for management of advanced or metastatic uterine serous carcinoma. Participants with early stage disease who received adjuvant platinum-based chemotherapy are also eligible if they recur within 12 months of their adjuvant therapy.
Must have received: anti-PD-1 therapy — for MSI-high or MMR-deficient tumors
those participants with MSI-high or MMR-deficient tumors must have already received prior therapy with a PD1 or PD-L1 immune checkpoint inhibitor or be deemed not to be a candidate for immune checkpoint therapy
Cannot have received: cell cycle checkpoint inhibitor
Participants may not have had prior receipt of a cell cycle checkpoint inhibitor (e.g., Chek1, Wee1, or ATR inhibition)
Lab requirements
Blood counts
absolute neutrophil count ≥1500/mcL; hemoglobin ≥9 g/dL (must be at least 2 weeks since any blood transfusion); platelets ≥100,000/mcL
Kidney function
creatinine ≤ 1.5x institutional ULN or estimated CrCl≥ 60 mL/min
Liver function
total bilirubin ≤ institutional upper limit of normal (ULN) or ≤1.5x ULN in patients with liver metastases or well-documented Gilbert's Syndrome; AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN or ≤5 × institutional ULN in patients with liver metastases
Cardiac function
NYHA class 2B or better
absolute neutrophil count ≥1500/mcL; hemoglobin ≥9 g/dL (must be at least 2 weeks since any blood transfusion); platelets ≥100,000/mcL; total bilirubin ≤ institutional upper limit of normal (ULN) or ≤1.5x ULN in patients with liver metastases or well-documented Gilbert's Syndrome; AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN or ≤5 × institutional ULN in patients with liver metastases; creatinine ≤ 1.5x institutional ULN or estimated CrCl≥ 60 mL/min; NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify